Cargando…

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib

BACKGROUND: Anlotinib significantly extended progression‐free survival (PFS) and overall survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment. METHODS: In this study, we retrospectively analyzed the efficacy and safety of anlotinib in the clinical practice and aimed to ide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Boyu, Xin, Lingli, Hou, Qingxiang, Yang, Bo, Zhang, Jing, Qi, Xiaoguang, Wei, Yingtian, Hu, Yi, Xiong, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209577/ https://www.ncbi.nlm.nih.gov/pubmed/33960145 http://dx.doi.org/10.1002/cam4.3941

Ejemplares similares

Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xiong, Qi, et al.
Publicado: (2021)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study
por: Liu, Zhujun, et al.
Publicado: (2018)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
por: Huang, Jing, et al.
Publicado: (2021)

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort
por: Wu, Hongyang, et al.
Publicado: (2022)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
por: Zhu, Shibin, et al.
Publicado: (2022)

First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma
por: Liang, Long, et al.
Publicado: (2022)

A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer
por: Wu, Di, et al.
Publicado: (2020)

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
por: Cheng, Ying, et al.
Publicado: (2021)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
por: Cheng, Ying, et al.
Publicado: (2020)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

High number of PD‐1 positive intratumoural lymphocytes predicts survival benefit of cytokine‐induced killer cells for hepatocellular carcinoma patients
por: Chang, Boyang, et al.
Publicado: (2018)

Development of a preoperative prognostic scoring system to predict benefits of hepatic resection in advanced hepatocellular carcinoma patients
por: Chen, Chang-Zhi, et al.
Publicado: (2021)

Survival benefit of gastrectomy for gastric cancer with peritoneal carcinomatosis: a propensity score‐matched analysis
por: Geng, Xiuwen, et al.
Publicado: (2016)

First-line ICIs in renal cell carcinoma
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma
por: Li, Qingqing, et al.
Publicado: (2022)

Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer
por: Che, Keying, et al.
Publicado: (2020)

Progression‐free survival assessed per immune‐related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune‐checkpoint inhibitors in lung cancer: A systematic review and meta‐analysis
por: Zhu, Guang‐Li, et al.
Publicado: (2021)

Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report
por: Wang, Jingyi, et al.
Publicado: (2023)

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021)

Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial
por: Shi, Jianhua, et al.
Publicado: (2021)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
por: Jiang, Bailing, et al.
Publicado: (2019)

Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib
por: Long, Yaping, et al.
Publicado: (2021)

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer
por: Zhan, Gouling, et al.
Publicado: (2023)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
por: Lin, Jingyang, et al.
Publicado: (2023)

CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer
por: Yang, Yuxin, et al.
Publicado: (2018)

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs
por: Zhou, Fei, et al.
Publicado: (2018)

Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2018)

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis
por: Zhou, Jun, et al.
Publicado: (2023)

Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin
por: Wang, Xiumei, et al.
Publicado: (2020)

Comment on “Expression of CD44 and the survival in glioma: a meta-analysis”
por: Hou, Chongxian, et al.
Publicado: (2020)

Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma
por: Zhang, Dandan, et al.
Publicado: (2022)

Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development
por: Barber, Paul R, et al.
Publicado: (2022)

Antitumor effects of anlotinib in thyroid cancer
por: Ruan, Xianhui, et al.
Publicado: (2018)

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
por: Martin, James M, et al.
Publicado: (2022)

High expression of sperm-associated antigen 5 correlates with poor survival in ovarian cancer
por: Zhang, Mei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fnt620n476sholtgsdudrju6m0